Midatech Pharma plc logo
Midatech Pharma plc MTP

Annual report 2024
added 02-07-2026

report update icon

Midatech Pharma plc Financial Statements 2011-2026 | MTP

Annual Financial Statements Midatech Pharma plc

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

- - - 79 M 20.9 K 23.6 K 17.1 M 27.1 M 56.9 M 66.2 M - - - -

Shares

- - - 80.5 M 9.16 K 9.16 K 620 K 521 K 366 K 285 K - - - -

Historical Prices

0.29 0.29 0.29 0.981 2.28 2.58 27.5 52 143 228 - - - -

Net Income

- - - -5.46 M -22.2 M -10.1 M -15 M -16.1 M -20.2 M -10.1 M -7.38 M -4.08 M - -

Revenue

- 381 K 699 K 578 K 343 K 674 K 1.94 M 989 K 6.92 M 1.38 M 157 K 147 K - -

Cost of Revenue

- - - - - - - 926 K 667 K 70 K - - - -

Gross Profit

- - - - - - - - -428 K 1.3 M - 147 K - -

Operating Income

- - - -7 M -23 M -11.3 M -11.8 M -13.3 M -9.65 M -12.9 M - - - -

EBITDA

- - - -7 M -23 M -11.3 M -11.8 M -13.3 M -14.8 M -12.2 M -7.56 M -4.25 M - -

Operating Expenses

- - - - 4.78 M 3.79 M 2.6 M 12.6 M 18.7 M 14.2 M - 4.65 M - -

General and Administrative Expenses

- - - - 4.95 M 3.84 M 4.39 M 3.15 M 9.22 M 7.93 M 4.4 M 1.81 M - -

All numbers in GBP currency

Quarterly Income Statement Midatech Pharma plc

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

All numbers in GBP currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Midatech Pharma plc MTP
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Midatech Pharma plc plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.83 2.17 % $ 4.53 M chinaChina
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 110.14 3.3 % $ 27.2 B germanyGermany
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Adagene Adagene
ADAG
$ 2.6 -1.12 % $ 146 M chinaChina
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.51 -0.52 % $ 8.45 B australiaAustralia
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 4.21 1.2 % $ 9.16 B israelIsrael
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
$ 1.49 7.19 % $ 279 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 221.8 -0.16 % $ 5 B danmarkDanmark
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
- 17.91 % $ 11.1 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 8.96 0.45 % $ 1.41 B britainBritain
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.46 2.46 % $ 373 M britainBritain
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
$ 14.49 -0.24 % $ 4.48 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Aytu BioScience Aytu BioScience
AYTU
$ 2.35 -1.81 % $ 14.8 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA